Signal transducer and activator of transcription 1 and matrix metalloproteinase 3 genetic expression and clinical significance on urothelial tumors after renal transplantation.
The objective of this study was investigate signal transducer and activator of transcription 1 and matrix metalloproteinase 3 genetic expression and clinical significance on urothelial carcinoma after renal transplantation. This study included 51 patients with histopathologically proven urothelial carcinoma, 16 of whom had undergone renal transplantation, and 35 others who had not and served as a control group. Human genome oligo-arrays were used to analyze the gene expression spectrum of the tumors. STAT1 and MMP3 expression in urothelial carcinoma was determined using real-time-polymerase chain reaction (RT-PCR) and immunohistochemistry staining. No prisoners or organs from prisoners were used in this study. Among the transplantation group, 35 genes were up-regulated. The functions of 23 genes were known or partly known. Additionally, 76 genes were down-regulated in the transplantation group. The function of 46 genes was known or partly known. Pathway analysis of differences in gene expression between the groups revealed 23 groups of pathways that exhibited statistical significance (P < .05). The differences in the levels of expression of STAT1 and MMP3 were significant (P < .05). Differences in gene expression profiles of STAT1 and MMP3 exist between patients who have and those who have not undergone renal transplantation. STAT1 and MMP3 may be potential targets for the chemoprevention of posttransplantation urothelial carcinoma.